₹-0.52
(Market cap
₹47 Cr
Revenue (TTM)
₹132 Cr
P/E Ratio
6.2
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹8 Cr
-
ROE
-9.4 %
-
ROCE
-7.8 %
-
Industry P/E
39.9
-
EV/EBITDA
4.1
-
Debt to Equity
0
-
Book Value
₹13.4
-
EPS
₹3.2
-
Face value
10
-
Shares outstanding
23,707,850
10 Years Aggregate
CFO
₹-5.40 Cr
EBITDA
₹-3.44 Cr
Net Profit
₹-4.95 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kabra Drugs
| -34.6 | -20.9 | -20.8 | 9.2 | 68.8 | 30.7 | 11.1 |
|
BSE Healthcare
| 18.8 | 2.8 | 8.7 | 17.1 | 23.1 | 14.8 | 12.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Kabra Drugs
| 202.8 | 78.1 | 21.7 | -11.3 | 342.9 | 37.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kabra Drugs
|
20.0 | 47.3 | 131.8 | 7.6 | 6.5 | 27.3 | 6.2 | 1.5 |
| 3,281.6 | 26,870.9 | 1,461.8 | 387.4 | 34.5 | 25.2 | 69.6 | 15.5 | |
| 813.5 | 16,000.2 | 7,784.0 | 688.5 | 10.6 | 14 | 23.1 | 2.7 | |
| 449.9 | 17,241.8 | 2,141.5 | 58.5 | 5.8 | 3.3 | 162.3 | 4.5 | |
| 836.7 | 20,739.4 | 5,632.3 | 662.4 | 17.2 | 14.3 | 31.3 | 4.2 | |
| 1,532.2 | 17,579.4 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 3.0 | |
| 218.7 | 29,103.3 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.6 | |
| 1,804.4 | 29,891.8 | 1,935.8 | 288.2 | 20.6 | 29.8 | 103.7 | 22.3 | |
| 403.4 | 16,284.0 | 3,600.2 | 221.0 | 9.7 | 5.6 | 73.7 | 3.4 | |
| 1,977.1 | 32,103.6 | 3,564.0 | 414.0 | 15.3 | 8.4 | 78.5 | 6.4 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Kabra Drugs
Manufacture of allopathic pharmaceutical preparations
-
Incorporated
1989
-
Chairman
--
-
Managing Director
N Aravind
-
Headquarters
Chennai, Tamil Nadu
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kabra Drugs
What is the current share price of Kabra Drugs Ltd Today?
The share price of Kabra Drugs Ltd is ₹19.97 (BSE) as of 28-Aug-2026 IST. Kabra Drugs Ltd has given a return of 68.83% in the last 3 years.
What is the current PB & PE ratio of Kabra Drugs Ltd?
The P/E ratio of Kabra Drugs Ltd is 6.24 times as on 28-Aug-2026, a 84 discount to its peers’ median range of 39.90 times.
The P/B ratio of Kabra Drugs Ltd is 1.49 times as on 28-Aug-2026, a 65 discount to its peers’ median range of 4.23 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
1.07 |
2024 |
0.00 |
-2.15 |
2023 |
0.00 |
-3.34 |
2022 |
0.00 |
-5.08 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Kabra Drugs Ltd?
The 52-week high and low of Kabra Drugs Ltd are Rs 35.52 and Rs 15.50 as of 29-Aug-2026.
What is the market cap of Kabra Drugs Ltd?
Kabra Drugs Ltd has a market capitalisation of ₹ 47 Cr as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kabra Drugs Ltd?
Before investing in Kabra Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.